Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/developmental-therapeutics-in-acute-myelogenous-leukemia-are-there-any-kLn0VcyBZO
References (37)
-
C. Mehta, G. Michelson, M. Salganik, J. Feaster, R. Allen, A. Cahill, J. Fox, S. Ketchum, F. Ravandi, H. Erba, G. Schiller, R. Stuart, N. Vey, E. Feldman (2011)
Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
J. Karp, A. Blackford, B. Smith, Katrina Alino, A. Seung, J. Bolaños-Meade, J. Greer, H. Carraway, S. Gore, Richard Jones, M. Levis, M. McDevitt, L. Doyle, J. Wright (2010)
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Leukemia research, 34 7
-
M. Sandvold, C. Galmarini, F. Myhren, G. Peters (2010)
The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside AnaloguesNucleosides, Nucleotides & Nucleic Acids, 29
-
R. Hawtin, David Stockett, J. Byl, R. McDowell, Nguyen Tan, M. Arkin, A. Conroy, Wenjin Yang, N. Osheroff, J. Fox (2010)
Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase IIPLoS ONE, 5
-
R. Advani, H. Hurwitz, M. Gordon, S. Ebbinghaus, D. Mendelson, H. Wakelee, U. Hoch, J. Silverman, N. Havrilla, C. Berman, J. Fox, R. Allen, D. Adelman (2010)
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing SchedulesClinical Cancer Research, 16
-
H. Fernandez, Zhuoxin Sun, Xiaopan Yao, M. Litzow, S. Luger, E. Paietta, J. Racevskis, G. Dewald, R. Ketterling, J. Bennett, J. Rowe, H. Lazarus, M. Tallman (2009)
Anthracycline dose intensification in acute myeloid leukemia.The New England journal of medicine, 361 13
-
B. Löwenberg, G. Ossenkoppele, W. Putten, H. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen‐Lavrencic, M. Lilienfeld-Toal, B. Biemond, E. Vellenga, M. Kooy, L. Verdonck, J. Beck, H. Döhner, A. Gratwohl, T. Pabst, G. Verhoef (2009)
High-dose daunorubicin in older patients with acute myeloid leukemia.The New England journal of medicine, 361 13
-
A. Burnett, N. Russell, M. McMullin, J. Kell, Sahra Ali, P. Moreton, A. Wei, L. Kjeldsen, R. Hills (2012)
A randomised comparison of Clofarabine versus low dose Ara-C as first line treatment for older patients with AML [Abstract]Blood, 120
-
E. Feldman, J. Lancet, J. Kolitz, E. Ritchie, G. Roboz, A. List, S. Allen, E. Asatiani, L. Mayer, C. Swenson, A. Louie (2011)
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
D. Breems, W. Putten, P. Huijgens, G. Ossenkoppele, G. Verhoef, L. Verdonck, E. Vellenga, G. Greef, E. Jacky, J. Lelie, M. Boogaerts, B. Löwenberg (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 9
-
F. Giles, N. Vey, D. Rizzieri, F. Ravandi, T. Prebet, G. Borthakur, T. Jacobsen, S. Hagen, Bo Nilsson, S. O’Brien (2012)
Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignanciesLeukemia, 26
-
P. Tardi, S. Johnstone, Natashia Harasym, S. Xie, T. Harasym, Natalia Zisman, P. Harvie, D. Bermudes, L. Mayer (2009)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.Leukemia research, 33 1
-
J Bennet, M Young, J Andersen (1997)
Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experienceCancer, 80
-
H. Kantarjian, G. Garcia-Manero, S. O'brien, S. Faderl, F. Ravandi, R. Westwood, S. Green, J. Chiao, P. Boone, J. Cortes, W. Plunkett (2010)
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 2
-
J. Abbas, R. Stuart (2012)
Vosaroxin: a novel antineoplastic quinoloneExpert Opinion on Investigational Drugs, 21
-
J. Byrd, K. Mrózek, R. Dodge, A. Carroll, C. Edwards, D. Arthur, M. Pettenati, S. Patil, K. Rao, M. Watson, P. Koduru, J. Moore, R. Stone, R. Mayer, E. Feldman, F. Davey, C. Schiffer, R. Larson, C. Bloomfield (2002)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).Blood, 100 13
-
A. Nazha, F. Ravandi, H. Kantarjian, Xuelin Huang, Sangbum Choi, G. Garcia-Manero, E. Jabbour, G. Borthakur, T. Kadia, M. Konopleva, J. Cortes, A. Ferrajoli, S. Kornblau, M. Andreeff, Z. Estrov, N. Daver, N. Pemmaraju, M. Du, M. Brandt, S. Faderl (2011)
Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)Blood, 120
-
H. Kantarjian, S. Faderl, G. Garcia-Manero, S. Luger, P. Venugopal, L. Maness, M. Wetzler, S. Coutre, W. Stock, D. Claxton, S. Goldberg, M. Arellano, S. Strickland, K. Seiter, G. Schiller, E. Jabbour, J. Chiao, W. Plunkett (2012)
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.The Lancet. Oncology, 13 11
-
B Lowenberg, JR Downing, A Burnett (1999)
Acute myeloid leukemiaNew Engl J Med, 341
-
S. Faderl, F. Ravandi, Xuelin Huang, Xuemei Wang, E. Jabbour, G. Garcia-Manero, T. Kadia, A. Ferrajoli, M. Konopleva, G. Borthakur, J. Burger, J. Feliu, H. Kantarjian (2012)
Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patientsCancer, 118
-
Xiaojun Liu, Yaqing Wang, Sherri Benaissa, A. Matsuda, H. Kantarjian, Z. Estrov, W. Plunkett (2010)
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.Blood, 116 10
-
J. Bennett, M. Young, J. Andersen, P. Cassileth, M. Tallman, E. Paietta, P. Wiernik, J. Rowe (1997)
Long‐term survival in acute myeloid leukemiaCancer, 80
-
J. Zeidner, Jonathan Gerber, A. Blackford, M. Litzow, M. Foster, L. Morris, I. Gojo, J. Lancet, P. Bose, R. Tibes, S. Strickland, J. Greer, Michelle Drye, K. Meads, A. Doyle, R. Little, J. Wright, J. Karp (2012)
Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)Blood, 120
-
J. Hołowiecki, S. Grosicki, T. Robak, S. Kyrcz‐Krzemień, S. Giebel, A. Hellmann, A. Skotnicki, W. Jędrzejczak, L. Konopka, K. Kuliczkowski, B. Zdziarska, A. Dmoszyńska, B. Marianska, A. Pluta, K. Zawilska, M. Komarnicki, J. Kłoczko, K. Sułek, O. Haus, B. Stella‐Hołowiecka, W. Baran, B. Jakubas, M. Paluszewska, A. Wierzbowska, M. Kiełbiński, K. Jagoda, on Group (2004)
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III studyLeukemia, 18
-
K. Breistøl, J. Balzarini, M. Sandvold, F. Myhren, M. Martinsen, E. Clercq, Ø. Fodstad (1999)
Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.Cancer research, 59 12
-
E. Estey (2001)
Therapeutic options for acute myelogenous leukemiaCancer, 92
-
J. Hołowiecki, S. Grosicki, S. Giebel, T. Robak, S. Kyrcz‐Krzemień, K. Kuliczkowski, A. Skotnicki, A. Hellmann, K. Sułek, A. Dmoszyńska, J. Kłoczko, W. Jędrzejczak, B. Zdziarska, K. Warzocha, K. Zawilska, M. Komarnicki, M. Kiełbiński, B. Piątkowska‐Jakubas, A. Wierzbowska, M. Wach, O. Haus (2012)
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 20
-
(2010)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. -
F. Giles, S. O'brien, J. Cortes, S. Verstovsek, C. Bueso-Ramos, J. Shan, S. Pierce, G. Garcia-Manero, M. Keating, H. Kantarjian (2005)
Outcome of patients with acute myelogenous leukemia after second salvage therapyCancer, 104
-
G. Roboz, J. Lancet, L. Cripe, F. Kashani, A. List, J. Fox, G. Michelson, J. Karp (2010)
Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.Journal of Clinical Oncology, 28
-
S. Faderl, M. Wetzler, D. Rizzieri, G. Schiller, M. Jagasia, R. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. Maris, T. Kovacsovics, S. Goldberg, K. Seiter, P. Hari, J. Greiner, N. Vey, C. Récher, F. Ravandi, E. Wang, M. Vasconcelles, D. Huebner, H. Kantarjian (2012)
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 20
-
S. O'Brien, D. Rizzieri, N. Vey, F. Ravandi, U. Krug, M. Sekeres, M. Dennis, A. Venditti, D. Berry, T. Jacobsen, K. Staudacher, T. Bergeland, F. Giles (2012)
Elacytarabine has single‐agent activity in patients with advanced acute myeloid leukaemiaBritish Journal of Haematology, 158
-
A. Azuma, P. Huang, A. Matsuda, W. Plunkett (2001)
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.Molecular pharmacology, 59 4
-
E. Estey (2007)
Acute myeloid leukemia and myelodysplastic syndromes in older patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 14
-
F. Appelbaum, H. Gundacker, D. Head, M. Slovak, C. Willman, J. Godwin, J. Anderson, S. Petersdorf (2006)
Age and acute myeloid leukemia.Blood, 107 9
-
Yates Jw, Wallace Hj, R. Ellison, J. Holland (1973)
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.Cancer chemotherapy reports, 57 4
-
R. Stuart, F. Kashani, L. Cripe, M. Maris, M. Cooper, S. Dakhil, R. Stone, F. Turturro, J. Fox, G. Michelson (2010)
Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.Journal of Clinical Oncology, 28
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0158-1
- pmid
- 23640069
- Publisher site
- See Article on Publisher Site
Abstract
Therapies for AML have remained mostly unchanged since the introduction of anthracyline- and cytarabine-based regimens in the 1970s. Though some changes have been made in the dosing of anthracylines, in the choice of consolidation regimens versus allogeneic stem cell transplant, and in supportive care, clinical outcomes remain poor for most patients. As we continue to strive for better treatment options to improve upon outcomes, different agents, both chemotherapeutic and targeted therapies, are being studied. Here we discuss new chemotherapeutic agents that show promise in recent clinical trials and attempt to answer the question if there are any new effective cytotoxic chemotherapy agents out there.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: May 3, 2013